Healthcare
Live Price
Offline$25.21
-2.74% today
1Y Change
+8.36%
Window
Jun 23, 2025 → Jun 16, 2026
Coverage: 247 bars · Jun 23, 2025 → Jun 16, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Pfizer Inc. (PFE) is a Healthcare stock with a market cap of $149.77B and listed on NYSE. The stock last traded around $25.21 and up 8.4% across the available one-year price window (Jun 23, 2025 → Jun 16, 2026). Baseline metrics include revenue growth of -1.6%, EPS growth of -4.2%, a dividend yield of 6.5%. What stands out right now is revenue -1.6%, EPS -4.2%, free cash flow -7.7% with operating margin 24.7% and ROIC 8.8%. The dividend matters to the case here, with a current yield around 6.5%. Valuation is more restrained than many high-expectation growth names at P/E 19.3 and price/sales 2.4. Overall, the current profile looks closer to a income-oriented value setup than a generic broad-market placeholder. Stock Foundry combines PFE price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
PFE
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
PFE Max Drawdown
-11.47%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for PFE and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$81.3B
-19.0% YoY
FY Net Income
$22.1B
-29.4% YoY
Free Cash Flow
$29.9B
+14.7% YoY
Revenue Growth
-1.6%
EPS Growth
-4.2%
Gross Margin
70.3%
Net Margin
12.4%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 62.6B | 63.6B | 59.6B | 100.3B | 81.3B |
| Gross Profit | 44.0B | 41.8B | 30.3B | 62.1B | 46.9B |
| Operating Income | 15.4B | 16.5B | 5.3B | 37.5B | 20.8B |
| EBITDA | 15.1B | 18.1B | 9.6B | 41.0B | 30.8B |
| Net Income | 7.8B | 8.0B | 2.1B | 31.4B | 22.1B |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 1.1B | 1.0B | 2.9B | 416M | 1.9B |
| Total Assets | 208.2B | 213.4B | 226.5B | 197.2B | 181.5B |
| Total Liabilities | 121.4B | 124.9B | 137.2B | 101.3B | 104.0B |
| Shareholder Equity | 86.5B | 88.2B | 89.0B | 95.7B | 77.2B |
| Total Debt | 67.4B | 67.0B | 70.8B | 34.9B | 37.0B |
| Net Debt | 66.3B | 66.0B | 68.0B | 34.4B | 35.1B |
Cash flow positioning
Latest Full Year
Operating Cash Flow
32.6B
+11.3% YoY
Capital Expenditures
2.7B
+16.2% YoY
Free Cash Flow
29.9B
+14.7% YoY
Key ratios
Gross Margin
70.3%
Operating Margin
24.7%
Net Margin
12.4%
ROE
8.7%
Debt / Equity
0.78x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.